Responsible Side Effects Management in Oncology

Study of pharmacovigilance in oncology. Monitoring and management of AEs during antineoplastic treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pharmacovigilance Antineoplastic Treatment Neoplasms Oncology

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

UHC Sestre milorsdnice

Zagreb, Croatia, Europe, 10 000, Croatia

About this study

Monitoring and management of AE's during antineoplastic treatment. Comparison of AE's reported by patient with the ones recognised by the oncologist, and vice versa, during antineoplastic treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

all cancer patients receiving systemic antineoplastic treatment, ECOG 0-2

Exclusion criteria

age <18, >75; other active and severe comorbidities; no solid cancer; IUC patients

Treatment and study plan

Primary outcomes

comparison of perspectives

Time frame: may 2016 until october 2016

comparison between patient's and oncologist's perspective on severity of AE's during antineoplastic treatment

Sponsors and collaborators

Lead sponsor

University Hospital Sestre Milosrdnice

Other

Registry information

Official study title

Comprehensive Antineoplastic Therapy Adverse Events Monitoring and Report

Acronym: R-SEMO

Important dates

Study start: 2017
Primary completion: 2017
Study completion: 2017
First posted: Nov 10, 2020
Registry last updated: Nov 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting